The paper “Perioperative chemotherapy and regional hyperthermia for high-risk adult-type soft tissue sarcomas” published in the European Journal of Cancer is undoubtedly of significance. Curious about the findings, I interviewed Professor Dr. Lars Lindner of Ludwig-Maximilians-Universität (LMU) in Munich. The renowned expert kindly agreed to respond to my questions regarding the various modalities compared in the paper, including CT, regional hyperthermia and immunotherapeutic agents, as well as the implications for the future. We have also produced an infographic that illustrates the long-term results of the EORTC 62961-ESHO 95 trial published in JAMA Oncology (Issels et al., 2018).Summary, Interview, Infographic
- 29th Jahrestagung der DEGRO (German Society for Radiation Oncology) Kassel, Germany June 22 – 24, 2023
- SarkomMeeting Frankfurt a. M., Germany June 23 – 24, 2023
- 27th SASRO Annual Meeting (Scientific Association of Swiss Radiation Oncology) Bern, Switzerland Aug. 31– Sep. 02, 2023
- 35th ESHO (European Society for Hyperthermic Oncology) Cologne, Germany Sep. 26 – 29, 2023
- 40th ÖGRO Jahrestagung 2023 (Austrian Society for Radiation Oncology) Vienna, Austria Oct. 13 – 14, 2023
Publication in EJC
The HEAT Trial
Pancreatic cancer: Hyperthermia trial demonstrates significantly improved post-recurrence survival
The randomized clinical trial "Hyperthermia European Adjuvant Trial" (HEAT) investigated regional hyperthermia (RHT) with cisplatin added to gemcitabine compared to chemotherapy with gemcitabine alone in the adjuvant treatment after resection of pancreatic cancer. The results show a significantly improved post-recurrence survival and a trend towards improved overall survival using Pyrexar Medical's BSD-2000 3D radiative hyperthermia system. Pancreatic cancer is one of the most common causes of cancer-related death worldwide. The HEAT trial was prematurely stopped in May 2018, when the modified FOLFIRINOX regimen replaced gemcitabine as standard therapy. The trial included a total of 117 patients with a median follow-up of 56.6 months.
Paul Turner, CTO at Pyrexar Medical Corporation covers “Present and Future Hyperthermia Technology Evolution”.
Paul Turner has been developing hyperthermia and ablation heat treatment methods for more than 40 years, including RF phased array systems for deep non-invasive and invasive phased arrays.